Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
| Previous Close | 985.02 |
| Open | 974.86 |
| Bid | 971.89 x 100 |
| Ask | 973.31 x 100 |
| Day's Range | 963.90 - 978.59 |
| 52 Week Range | 684.81 - 998.33 |
| Volume | |
| Avg. Volume | 434,498 |
| Market Cap | 107.229B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 29.07 |
| EPS (TTM) | 33.48 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1,060.68 |
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
Simply Wall St.Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
Insider MonkeyThe Biggest Biotechnology Company in Europe
We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]
